Plain-English translation of NCT07187570 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called dapagliflozin can help prevent atrial fibrillation (an irregular heart rhythm) from coming back after you receive a procedure to restore your normal heartbeat. Researchers will compare people taking this medication daily to people receiving standard care to see if the medication reduces how often the irregular rhythm returns.
Atrial fibrillation often comes back after treatment, and doctors are looking for ways to help keep the heart rhythm stable longer. This trial is testing whether this medication, which is already used for other heart and kidney conditions, might also help prevent the irregular heartbeat from recurring.
You likely qualify if…
You likely don't qualify if…
If you join, you'll take either the medication or no additional treatment once daily for up to 56 days, then undergo your scheduled electrical heart rhythm procedure. During the 56-day study period, you'll use a small handheld device to record your heart rhythm and send the information to the research team so they can track whether your heartbeat stays regular.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Sweden